Last reviewed · How we verify
Placebo of clopidogrel and Asprin — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of clopidogrel and Asprin (Placebo of clopidogrel and Asprin) — Beijing Tiantan Hospital. This is a placebo control arm containing inactive formulations of clopidogrel and aspirin used in a clinical trial to establish efficacy of the active antiplatelet agents.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of clopidogrel and Asprin TARGET | Placebo of clopidogrel and Asprin | Beijing Tiantan Hospital | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of clopidogrel and Asprin CI watch — RSS
- Placebo of clopidogrel and Asprin CI watch — Atom
- Placebo of clopidogrel and Asprin CI watch — JSON
- Placebo of clopidogrel and Asprin alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of clopidogrel and Asprin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-clopidogrel-and-asprin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab